Accountable care organizations (ACOs), a creation of the controversial Accountable Care Act (ACA), are among the most discussed innovations in healthcare delivery. Now, life science companies are taking a long, hard look at ACOs to determine what effect they may have on sales of existing therapies and the incentives to create new ones, particularly following the recent publication of the Centers for Medicare & Medicaid Services' (CMS) long-anticipated proposed regulations for the Medicare Shared Services Program (MSSP). The MSSP provides guidance on how ACOs will be constructed and operated and offers clues as to how Medicare ACOs may affect the pharmaceutical and biotechnology industries.
Read the article here.